Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 6/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457615 | 1.00 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL11339655 | 0.84 | CYP2A6 (0.53) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL2581205 | 0.83 | CYP2A6 (0.51) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL30453664 | 0.83 | CYP2A6 (0.51) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL306921 | 0.79 | CSNK2A1 (0.49) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL9458439 | 0.79 | IDO1 (0.50) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL29748318 | 0.79 | CYP3A4 (0.46) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL30641468 | 0.79 | MAPT (0.47) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL29537704 | 0.79 | CSNK2A1 (0.49) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL5652811 | 0.79 | CYP3A4 (0.46) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457153-B | Industrial preparation method of 2,4, 5-trifluoro-phenylacetic acid | 台州臻挚生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-113735715-A | Bis (2, 4-dichlorophenethyl) amine hydrochloride and preparation method thereof | 山东金城柯瑞化学有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-113292493-A | Preparation method of 5, 7-dichloro-1, 2,3, 4-tetrahydroisoquinoline | 上海立科化学科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-112457153-A | Industrial preparation method of 2,4, 5-trifluoro-phenylacetic acid | 杭州臻挚生物科技有限公司 | 2021-03-09 | — | — | CN | claimed |
| CN-108709944-B | Method for simultaneously detecting 6 chlorobenzene acetonitrile serving as nitrogenous aromatic disinfection by-product in drinking water | 同济大学 | 2021-02-12 | — | — | CN | claimed |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260014260-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12516055-B2 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | TRUSTEES OF TUFTS COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4623032-A2 | YELLOW METHINE DYES AND THEIR USE FOR DYEING PLASTICS | LANXESS Deutschland GmbH (DE) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-4118461-A | FUNGICIDES | ROHM AND HAAS COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4115578-A | FUNGICIDES | ROHM AND HAAS COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4107205-A | α-Aryl-α,α-bis[ω-(disubstituted amino)alkyl]acetamides and related compounds | G. D. SEARLE & CO. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4105762-A | Metal salt complexes of 1-substituted aralkyl imidazoles, and methods and compositions for controlling phytopathogenic fungi using them | ROHM AND HAAS COMPANY (US) | 1978-08-08 | — | — | US | disclosed |
| US-4073921-A | FUNGICIDES | ROHM AND HAAS COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4005218-A | Antiparasitic salicylanilide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-01-25 | — | — | US | disclosed |
| US-3979444-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES | THE UPJOHN COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014260-A1 | MDM2 DEGRADER | MDM2, TP53, ADRM1 | CYP1A2 2117/4885CYP3A4 2347/4885CYP2C9 2454/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | CYP1A2 2501/4885CYP3A4 2594/4885CYP2C9 3105/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | CYP1A2 4023/4885CYP3A4 4255/4885CYP2C9 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.